Ascletis Pharma Inc (1672.HK), an R&D driven, commercial-stage biotechnology company, has named Dr Handan He as its new chief scientific officer, it was reported yesterday.
Dr He is to report to Dr Jinzi J Wu, founder, Ascletis chairman and CEO.
Dr He was a former global head of Computational, Biopharmaceutics and Translational PK/PD at Novartis Pharmaceutical Corporation, New Jersey, USA. Dr He joined Novartis, New Jersey in 1997.
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers
INOVIO announces inducement grant to new employee
AbbVie's Allergan Aesthetics announces Natrelle supplier agreement with Vizient
Karyopharm Therapeutics awards inducement grants to new employees
POLYTECH Health & Aesthetics announces Poland expansion
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar